Table 2 Fitted ADC and IVIM parameter estimates following vasomodulator challenge

f

Furosemide

12.0 ± 1.4

10.1 ± 1.0 ^b

17.1 ± 1.0

12.0 ± 1.5^a

9.6 ± 1.7

8.2 ± 1.3 ^b

(%)

Angiotensin II

19.3 ± 1.5

18.7 ± 1.6

23.9 ± 2.9

21.6 ± 2.1

15.3 ± 1.5

13.3 ± 1.3

Hydralazine

133.9 ± 5.9

100.2 ± 6.6^a

130.3 ± 7.2

96.8 ± 8.8^a

139.3 ± 4.0

109.6 ± 5.4^a

D

Furosemide

118.8 ± 5.8

138.8 ± 5.0^a

117.5 ± 7.7

137.4 ± 7.9^a

123.5 ± 5.4

141.6 ± 4.3^a

(10⁻⁵ mm²s⁻¹)

Angiotensin II

118.8 ± 7.0

115.0 ± 4.4

116.4 ± 7.3

110.7 ± 4.7

129.1 ± 8.7

123.8 ± 5.7

Hydralazine

130 ± 6.0

97.9 ± 7.1^a

126.6 ± 6.5

87.9 ± 8.9^a

139.0 ± 4.0

111.8 ± 6.2^a

ADC

Furosemide

117.1 ± 5.8^a

136.2 ± 5.7^a

114.1 ± 9.1^a

134.5 ± 8.6^a

122.7 ± 5.5^a

141.1 ± 5.6^a

(10⁻⁵ mm²s⁻¹)

Angiotensin II

110.9 ± 7.7

110.9 ± 3.9

103.1 ± 8.1

102.2 ± 4.7

126.0 ± 8.8

122.2 ± 2.7

Termination

91.3 ± 9.5

68.0 ± 4.3^a

84.1 ± 9.8

60.5 ± 5.3^a

100.7 ± 10.2

79.0 ± 10.7

Hydralazine

4.0 ± 0.2

5.0 ± 0.2^a

3.3 ± 0.4

5.0 ± 0.2^a

4.3 ± 0.3

4.9 ± 0.2^a

D*

Furosemide

3.6 ± 0.2

3.8 ± 0.1

3.2 ± 0.3

3.7 ± 0.2

3.8 ± 0.2

3.6 ± 0.2

(10⁻² mm²s⁻¹)

Angiotensin II

4.3 ± 0.5

5.1 ± 0.3

4.2 ± 0.4

4.5 ± 0.3

4.3 ± 0.6

5.2 ± 0.4 ^b

Hydralazine

38.7 ± 1.7

65.6 ± 1.9^a

48.1 ± 3.4

96.7 ± 9.2^a

25.2 ± 0.9

35.6 ± 3.7^a

fD*

Furosemide

38.4 ± 5.0

32.5 ± 3.2

48.4 ± 5.0

37.8 ± 4.3^a

29.9 ± 4.7

25.0 ± 2.7

(10⁻⁴ mm²s⁻¹)

Angiotensin II

71.2 ± 11.5

80.8 ± 10.8

76.8 ± 9.4

83.0 ± 12.9

59.0 ± 12.3

62.8 ± 9.5